BioCardia to Present at Major Heart Failure Congress
BioCardia, Inc. [NASDAQ: BCDA], a leading company in cellular and cell-derived therapeutics, is excited to announce its participation in an important healthcare event focusing on heart failure treatment. The event will take place in Frankfurt, Germany, showcasing the latest innovations in cardiovascular therapies.
Event Highlights and Presentation Details
Peter Altman, PhD, the President and CEO of BioCardia, will deliver a key presentation titled “Intramyocardial Cell Therapy for Ischemic Heart Failure of Reduced Ejection.” This discussion aims to shed light on groundbreaking therapies that improve the lives of patients suffering from heart failure.
Meeting Overview
The program, part of the CSI Focus on Devices in Heart Failure, is set to provide in-depth insights into novel device-based therapies specifically targeting heart failure. Attendees can expect a compelling overview of the latest advancements in restoring heart function.
Session Specifics
This vital session will cover myocardial structural therapies aimed at enhancing ventricular function. Attendees are encouraged to take part in this knowledge-sharing experience, creating opportunities for collaboration and innovation in the field.
Understanding Device-Based Therapies
CSI Focus D-HF brings together industry experts and innovators to discuss various strategies for heart failure treatment. This includes new approaches for ventricle restoration and advanced monitoring systems that play a significant role in managing heart health.
Advancements in Cardiac Therapy
The congress will highlight how device-based therapies can potentially improve cardiac output and overall patient well-being. These developments exemplify BioCardia’s commitment to pioneering solutions that change the landscape of heart failure treatment.
About BioCardia
BioCardia, Inc. is based in Sunnyvale, California, and has established itself as a frontrunner in the development of cellular therapeutics for both cardiovascular and pulmonary diseases. Their innovative platforms, such as CardiAMP® and CardiALLO™, are at the forefront of bringing new hope to patients through clinical advancements.
Core Technologies
BioCardia's therapies are supported by their Helix™ biotherapeutic delivery system and Morph® vascular navigation platform. These technologies allow precise treatment applications, leading to improved patient outcomes.
Frequently Asked Questions
What is BioCardia, Inc. known for?
BioCardia is known for its advancements in cellular and cell-derived therapeutics specifically targeting cardiovascular diseases.
What is the main focus of BioCardia's presentation at the congress?
The presentation focuses on intramyocardial cell therapy for treating ischemic heart failure with reduced ejection fraction.
Where is the congress being held?
The congress will be held in Frankfurt, Germany, and will feature numerous discussions and presentations on heart failure therapies.
What are the key technologies developed by BioCardia?
BioCardia has developed the Helix™ biotherapeutic delivery system and Morph® vascular navigation platform, enhancing treatment efficacy.
How does BioCardia contribute to the field of heart disease?
BioCardia contributes by pioneering innovative therapies that help manage and treat serious heart conditions, improving patient outcomes and quality of life.
